Navigation Links
Shire reports analysis examining emotional lability in children with ADHD taking Vyvanse
Date:11/13/2009

PHILADELPHIA November 12, 2009 Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced findings from a post hoc analysis examining emotional lability from Phase 3 study data with Vyvanse. In this study, Vyvanse demonstrated significant improvement in Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms as measured by the ADHD Rating Scale IV (ADHD-RS IV) and Connors' Parent Rating Scale-Revised Short (CPRS-RS) in children with ADHD aged 6 to 12 years. The post hoc analysis showed that patients demonstrated an improvement in emotional lability composite CPRS-RS scores while taking Vyvanse as compared to placebo. These results were presented recently at a psychiatric meeting in Honolulu.

"Children taking ADHD medications can experience emotional lability, often described as frequent changes in emotions or mood. Therefore, evaluating the impact of ADHD treatments, including Vyvanse, on children's emotional lability may be important for parents and health care professionals when assessing a child's treatment plan," said Ann C. Childress, MD, study investigator and president of the Center for Psychiatry and Behavioral Medicine, Inc. in Las Vegas.

About the Analysis and Study

This post hoc analysis was based on a Phase 3, randomized, double-blind, placebo-controlled trial with forced-dose escalation of Vyvanse (30, 50, or 70 mg/d) or placebo in 285 children aged 6 to 12 years with ADHD. The primary end point of the study was the ADHD-RS IV, and secondary end points included CPRS-RS and safety. The CPRS-RS scale in its entirety contains 27 items to evaluate children's behaviors based on parents' responses. Each of the CPRS-RS 27 items is scored from zero as "Not At All True/Never, Seldom" up to three as "Very Much True/Very Often, Very Frequent." Parents completed the CPRS at 10 AM, 2 PM, and 6 PM at study start and on the day before their children made the weekly study visits. In the post hoc analysis, the children's emotional lability score was determined based on the sum of their average scores from three items on the CPRS-RS: angry/resentful, loses temper, and irritable. Patients were then grouped into those with and without prominent emotional lability at study start (scores greater than three versus scores of three or less) so that each group could be evaluated separately.

Overall, the children's average emotional lability scores significantly improved with Vyvanse treatment compared with placebo across the day (10 AM, 2 PM, and 6 PM) from study start to end (all P≤.0004).

As expected, treatment with Vyvanse, compared to placebo, did not result in significant improvements in emotional lability scores from study start to end in those without prominent emotional lability prior to treatment. However, treatment with Vyvanse, compared to placebo, yielded significant improvements in the emotional lability scores of those children with prominent emotional lability (P<.0001).

The most common treatment-emergent adverse events reported in this study for patients taking Vyvanse were decreased appetite, insomnia, upper abdominal pain, headache, irritability, vomiting, weight decrease, nausea, dizziness, and dry mouth.

Vyvanse, which was introduced in the United States in July 2007 for the treatment of ADHD in children aged 6 to 12 years and approved in April 2008 to treat ADHD in adults, is currently available in six dosage strengths of 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, and 70 mg.

Vyvanse is a therapeutically inactive prodrug stimulant, in which d-amphetamine is covalently bonded to l-lysine, and after oral ingestion it is converted to pharmacologically active d-amphetamine. The conversion of Vyvanse to d-amphetamine is not affected by gastrointestinal pH and is unlikely to be affected by alterations in GI transit times.


'/>"/>

Contact: Matt Cabrey
mcabrey@shire.com
484-595-8248
Porter Novelli
Source:Eurekalert

Related medicine news :

1. Exciting New Plan from John Edwards on AIDS; Plan is Bold and Achievable, say New Hampshire Activists
2. URAC CEO Testifies Before New Hampshire Legislators Regarding New URAC Standards for Pharmacy Benefit Management
3. Families Invited to Celebrate Shire Day at Boston Childrens Museum
4. New Hampshire: 1st in the Nation Primary State Takes a Stand on E-Prescribing
5. Shire to Present New Scientific Data on its ADHD Treatments at a Major Psychiatric Meeting
6. New Hampshire AIDS Group Calls on Huckabee to Disavow His 1992 Statement
7. VIDEO from Medialink and Shire plc: Rare Diseases Must Be Top of the Health Agenda
8. Shire Launches Patient Education Forums on Better Managing the Challenges of Ulcerative Colitis
9. AUDIO from Medialink and Shire: What It Means to be an Adult With ADHD
10. Shire to present ADHD treatments scientific data at American Psychiatric Assoc. Meeting
11. Anthem Blue Cross and Blue Shield in New Hampshire Announces Unique Enhancement to its ePrescribing Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... , ... October 13, 2017 , ... ... the certification process to promote standards of excellence for the field of eating ... for March 22 – 25, 2018 in Orlando, Florida at the Omni Resort ...
(Date:10/13/2017)... ... October 13, 2017 , ... Lori R. Somekh, founder ... of ElderCounsel, a national organization of elder law and special needs planning attorneys. “Membership ... rules. It also provides a forum to network with elder law attorneys nationwide,” said ...
(Date:10/13/2017)... BASKING RIDGE, N.J. (PRWEB) , ... October 13, 2017 , ... ... second annual Holly Day Market. Featuring a collection of specialty vendors and unique items ... myriad of personalized and quality-focused health and wellness services offered by the VNA. ...
(Date:10/13/2017)... ... 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, ... and least understood books in the Holy Scriptures, Revelation. The Book of Revelation paints ... for centuries. Many have tossed it off as mere rubbish, but Yisrayl Hawkins says ...
(Date:10/13/2017)... ... 13, 2017 , ... “The Journey: From the Mountains to the Mission Field”: ... souls in the Philippines. “The Journey: From the Mountains to the Mission Field” is ... Bible. She has taught all ages and currently teaches a class of ladies at ...
Breaking Medicine News(10 mins):
(Date:10/4/2017)... Oct. 4, 2017 OBP Medical ... illuminating medical devices, today announced regulatory approval from ... Agency (or Agência Nacional de Vigilância Sanitária (ANVISA)) ... cordless surgical retractor with integrated LED light source ... illumination and exposure of a tissue pocket or ...
(Date:10/2/2017)... 2017  AllianceRx Walgreens Prime, the combined central specialty ... pharmacy benefit manager Prime Therapeutics LLC (Prime), today officially ... the unveiling of new signage at its headquarters in ... at a few other company-owned facilities across the country. ... some of whom will begin to see the AllianceRx ...
(Date:9/28/2017)... 2017 Hill-Rom Holdings, Inc. (NYSE: HRC), will ... and webcast on Friday, November 3, 2017, beginning at ... at approximately 8:30 a.m. (CDT) / 9:30 a.m. (EDT). ... financial performance and guidance for 2018, Hill-Rom executives will ... operational performance, and long-range financial outlook through 2020. ...
Breaking Medicine Technology: